Media coverage about Quanterix (NASDAQ:QTRX) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Quanterix earned a coverage optimism score of 0.03 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.4341252669605 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Quanterix (QTRX) traded down $0.71 on Friday, hitting $21.47. The stock had a trading volume of 93,476 shares, compared to its average volume of 158,540. Quanterix has a one year low of $15.56 and a one year high of $23.70.
In other news, insider E Kevin Hrusovsky purchased 34,000 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was acquired at an average price of $15.00 per share, with a total value of $510,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David R. Walt purchased 200,000 shares of the stock in a transaction that occurred on Monday, December 11th. The stock was purchased at an average cost of $15.00 per share, with a total value of $3,000,000.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 500,000 shares of company stock valued at $7,500,000.
WARNING: This article was first posted by Week Herald and is owned by of Week Herald. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://weekherald.com/2017/12/29/quanterix-qtrx-earning-somewhat-positive-media-coverage-report-shows.html.
Quanterix Corporation is a United States-based company, which is a developer of tools in high definition diagnostics. The Company offers single molecule array (Simoa) platform, whcich uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.